Background: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases.
Objectives: To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options.
Results: /Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695253 | PMC |
| http://dx.doi.org/10.1016/j.crphar.2021.100071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fecal Calprotectin Correlates with Disease Extent but Remains a Reliable Marker of Mucosal Healing in Ulcerative Colitis.
Am J Gastroenterol
January 2025
Department of Internal Medicine, Unit of Gastroenterology, Stavanger University Hospital, Stavanger, Norway.
Background And Aims: Fecal calprotectin (FC) is a marker of mucosal inflammatory activity in ulcerative colitis (UC). FC levels may also be influenced by the extent of disease. We aimed to examine the relationships between FC, mucosal activity, and disease extent, and to assess how disease extent affects the diagnostic accuracy of FC.
View Article and Find Full Text PDF[Not Available].
Gastroenterol Hepatol
January 2025
Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.
Etrasimod is a synthetic, non-biological, orally administered small molecule sphingosine-1-phosphate receptor (S1PR) modulator. Etrasimod was approved by the Food and Drug Administration in 2023 and by the European Medicine Agency in 2024, constituting a new therapeutic option for the treatment of moderately to severely active ulcerative colitis in patients 16 years of age and older in the European Union. Its efficacy and tolerability have been demonstrated in several clinical trials both as induction and maintenance treatment, as well as in long-term extension studies.
View Article and Find Full Text PDFHyperbaric Oxygen Therapy Regimens, Treated Conditions, and Adverse Effect Profile: an Undersea and Hyperbaric Medical Society Survey Study.
Undersea Hyperb Med
January 2025
Hansjorg Wyss Department of Plastic Surgery, NYU Grossman School of Medicine, New York, NY.
Introduction: When administering HBO , pressures can range from 1.4 atmospheres absolute (ATA) to 3 ATA. While different treatment profiles have been proposed, there is a paucity of literature comparing the effectiveness and risk profile associated with different pressures treating the same condition.
View Article and Find Full Text PDFThe association between inflammatory bowel disease and risk of prostate cancer: a population-based retrospective study based on Korean National Health Insurance Service database.
Prostate Int
September 2024
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
Background: The aim of this study was to determine whether inflammatory bowel disease (IBD) is associated with the risk of developing prostate cancer (PCa) through a population-based study.
Materials And Methods: Male patients aged ≥40 years, diagnosed with IBD from 2010 to 2013 and without IBD were identified and followed-up till 2019. A matched cohort of male patients with and without IBD in a ratio of 1:4 was created based on age, income level, and Charlson comorbidity index.
Adalimumab is a recombinant human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha). It has become an important drug in the treatment of inflammatory bowel diseases (IBD), which do not respond to initial medical treatment. The case of a patient with ulcerative proctitis is presented, who developed acute pleuropericarditis, after starting treatment with Adalimumab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!